Alkermes plc (ALKS)
| Market Cap | 8.25B +67.9% |
| Revenue (ttm) | 1.67B +10.8% |
| Net Income | 66.12M -81.0% |
| EPS | 0.39 -81.3% |
| Shares Out | 167.76M |
| PE Ratio | 126.62 |
| Forward PE | 31.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 660,875 |
| Open | 49.23 |
| Previous Close | 49.21 |
| Day's Range | 48.46 - 49.35 |
| 52-Week Range | 25.17 - 55.67 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 56.00 (+13.91%) |
| Earnings Date | Jul 28, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $56.0, which is an increase of 13.91% from the latest price.
News
Alkermes’ alixorexton featured in published Phase 2 study of narcolepsy
Alkermes (ALKS) announced the publication of data from the Vibrance-1 phase 2 study of alixorexton in adults with narcolepsy type 1, or NT1, in The Lancet Neurology. Alixorexton is a…
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neuro...
Alkermes price target raised to $61 from $60 at JPMorgan
JPMorgan raised the firm’s price target on Alkermes (ALKS) to $61 from $60 and keeps a Neutral rating on the shares.
Alkermes price target raised to $58 from $48 at Baird
Baird raised the firm’s price target on Alkermes (ALKS) to $58 from $48 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and…
Alkermes sinks 5% to $50.05 following Q2 report
08:45 EDT Alkermes (ALKS) sinks 5% to $50.05 following Q2 report
Alkermes Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by proprietary products and the successful integration of LUMRYZ. The orexin pipeline advanced with positive clinical data, while commercial execution and expanded access for key brands support long-term growth.
Alkermes Earnings release: Q2 2026
Alkermes released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Alkermes Slides: Q2 2026
Alkermes has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Alkermes Quarterly report: Q2 2026
Alkermes has published its Q2 2026 quarterly earnings report on July 28, 2026.
Alkermes reaffirms FY26 revenue view $1.73B-$1.84B, consensus $1.81B
Sees adjusted EBITDA $370M-$410M
Alkermes reports Q2 revenue $496.0M, consensus $457.36M
Reports GAAP EPS 0c vs. 52c last year. The company said, “As we move into the second half of the year, we have clear priorities and a sharp focus on…
Alkermes reports Q2 EPS 0c, consensus 29c
Reports Q2 revenue $496M, consensus $457.36M. “As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD…
Alkermes says Blair Jackson to assume CEO role on August 1
“The second quarter was marked by strong commercial performance and meaningful progress across our pipeline as we continued to execute on our strategic priorities. Our commercial portfolio consists of...
Alkermes price target raised to $65 from $43 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Alkermes (ALKS) to $65 from $43 and keeps an Overweight rating on the shares. With Alkermes’ shares up 88%…
Alkermes plc Reports Second Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentat...
Alkermes price target raised to $63 from $45 at Stifel
Stifel raised the firm’s price target on Alkermes (ALKS) to $63 from $45 and keeps a Buy rating on the shares. Shares have had a significant run, largely on the…
Alkermes to Report Second Quarter Financial Results on July 28, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quar...
Alkermes announces results from planned interim analysis of LTE of alixorexton
Alkermes (ALKS) announced results from a planned interim analysis of the ongoing long-term extension, LTE, study evaluating alixorexton in adults with narcolepsy type 1, NT1, and narcolepsy type 2, NT...
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcol...
Alkermes resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Alkermes (ALKS) with a Neutral rating and $60 price target The company is entering a new phase, establishing itself as a key player in the sleep…
Alkermes price target raised to $65 from $53 at Mizuho
Mizuho raised the firm’s price target on Alkermes (ALKS) to $65 from $53 and keeps an Outperform rating on the shares. The stock is up 51% since the Q1 earnings…
Alkermes downgraded to Underperform from Neutral at BofA
BofA analyst Jason Gerberry downgraded Alkermes (ALKS) to Underperform from Neutral with a $38 price target With shares up 92% year-to-date, the firm acknowledges investor excitement over Alkermes’ or...
Alkermes price target raised to $65 from $44 at Wells Fargo
Wells Fargo raised the firm’s price target on Alkermes (ALKS) to $65 from $44 and keeps an Overweight rating on the shares. The firm recently flagged Alkermes as a top…
Alkermes price target raised to $61 from $54 at Needham
Needham raised the firm’s price target on Alkermes (ALKS) to $61 from $54 and keeps a Buy rating on the shares.
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 ...